Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Damira Vulas

Psychiatry Chevy Chase, MD Medical Doctor

NPI 1780066621 CMS profile 1371808

5454 Wisconsin Ave Ste 1275, Chevy Chase, MD 20815

Open in the dashboard

General payments

$3,099

142 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Damira Vulas of Chevy Chase, MD is reported in the CMS Open Payments database as having received $3,099 across 142 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $44 2
2024 General $785 39
2023 General $767 30
2022 General $673 30
2021 General $786 39
2020 General $44 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Damira Vulas
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Damira Vulas were reported at $44. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Damira Vulas Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $44 $119 $36–$372 $114
2021 $786 $143 $43–$576 $132
2022 $673 $153 $50–$590 $149
2023 $767 $170 $56–$651 $160
2024 $785 $179 $57–$673 $164
2025 $44 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Supernus Pharmaceuticals, Inc. $590 28 payments
  2. ITI, Inc. $575 21 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $465 23 payments
  4. AbbVie, Inc. $410 23 payments
  5. Otsuka America Pharmaceutical, Inc. $312 15 payments
  6. Sunovion Pharmaceuticals Inc. $230 11 payments
  7. Lundbeck LLC $218 11 payments
  8. Tris Pharma Inc $118 1 payment
  9. Bausch Health US, LLC $74 4 payments
  10. Axsome Therapeutics, Inc. $48 2 payments
  11. Other $59 3 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $3,099 142 payments
Products named General payments · program years 2020–2025
  1. CAPLYTA $575 21 payments
  2. TRINTELLIX $438 22 payments
  3. VRAYLAR $410 23 payments
  4. QELBREE Psychology $354 17 payments
  5. REXULTI Psychiatry $312 15 payments
  6. Qelbree Viloxazine Hydrochloride $236 11 payments
  7. LATUDA $230 11 payments
  8. REXULTI Psychiatry $218 11 payments
  9. Quillichew ER $118 1 payment
  10. Dyanavel XR $118 1 payment
  11. Other $326 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record